Previous 10 | Next 10 |
home / stock / biovf / biovf news
The FDA has signed off on Seelos Therapeutics' ( SEEL +7.3% ) IND for a Phase 2b/3 clinical trial evaluating SLS-005 (trehalose) in patients with mucopolysaccharidosis type III (Sanfilippo syndrome), an inherited disorder characterized by delayed speech and behavioral problems that is ...
Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) has entered into an agreement to sell a FDA Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of $95M. More news on: Swedish Orphan Biovitrum AB (publ), Healthcare stocks news, Read more ...
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2019 Earnings Conference Call July 17, 2019 03:00 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Financial Officer Milan Zdravkovic - Head of Research & Development and Chief Medical Of...
The following slide deck was published by Swedish Orphan Biovitrum AB (publ) in conjunction with their 2019 Q2 earnings Read more ...
Swedish Orphan Biovitrum AB (publ) ( OTCPK:BIOVF ): Q2 Non-GAAP EPS of SEK2.12; GAAP EPS of SEK1.70. More news on: Swedish Orphan Biovitrum AB (publ), Earnings news and commentary, Healthcare stocks news, Read more ...
STOCKHOLM , July 17, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the second quarter 2019. Total revenue was SEK 3,163 M (2,289), with 38 per cent revenue growth in the quarter compared with Q2 2018 (32 per cent at constant exc...
STOCKHOLM , July 16, 2019 /PRNewswire/ -- Sobi™ has established the Sobi Scientific Innovation Awards, with a focus on the future of haemophilia care, to recognise innovation and scientific excellence in haemophilia research. Entries will be assessed by an Adjudication Committee...
STOCKHOLM , July 8, 2019 /PRNewswire/ -- On 17 July, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2019. Financial analysts and media are invited to participate in a telephone conference, which will include a presentatio...
STOCKHOLM , June 18, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces that new research demonstrating the effects of emapalumab in patients with macrophage activation syndrome (MAS), a form of secondary haemophagocytic lymphohistiocytosis (HLH)...
Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) has signed an agreement to acquire (from Novimmune's shareholders) a newly established company owning emapalumab and related assets (previously announced exclusive licence agreement with Novimmune will be superseded). More news on: Swedish Orph...
News, Short Squeeze, Breakout and More Instantly...
Swedish Orphan Biovit Ord Company Name:
BIOVF Stock Symbol:
OTCMKTS Market:
Repsol S.A ADR (REPYY) is expected to report $0.86 for Q1 2024 Chugai Pharmaceutical Co Ltd ADR (CHGCY) is expected to report for Q1 2024 CBIZ Inc. (CBZ) is expected to report $1.57 for Q1 2024 Financial Institutions Inc. (FISI) is expected to report $0.66 for Q1 2024 Caterpillar ...
CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...
Swedish Orphan Biovitrum AB (BIOVF) is expected to report $0.09 for Q3 2023